OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Hunter on the Development of Targeted Approaches Beyond JAK Inhibition in Myelofibrosis

January 16th 2025

Anthony M. Hunter, MD, discusses the development of, and future roles for JAK, BET, and BCL2/BCL-XL inhibitors in myelofibrosis.

Dr Westbrook on Clinical Trials That Have Shaped the Non-ccRCC Treatment Paradigm

January 16th 2025

Thomas Westbrook, MD, discusses the non–clear cell renal cell carcinoma research that informs his clinical practice.

Dr Lee on the Efficacy of Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer

January 16th 2025

John K. Lee, MD, PhD, discusses the EV-302 trial of frontline enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial cancer.

Dr Kim on The Efficacy and Safety of Odronextamab in R/R MZL

January 15th 2025

Tae Min Kim, MD, PhD, discusses the efficacy of odronextamab monotherapy in patients with relapsed/refractory marginal zone lymphoma.

Dr Goldsberry on the Risk of Secondary Malignancies With PARP Inhibitors in Ovarian Cancer

January 15th 2025

Whitney Goldsberry, MD, discusses the potential risk of secondary malignancies in patients with ovarian cancer receiving PARP inhibitors.

Dr Ali on the Need for Novel Targets Beyond BCMA in Multiple Myeloma

January 15th 2025

Syed Abbas Ali, MBBS, discusses the identification of novel targets for patients with multiple myeloma who previously progressed on BCMA-targeted agents.

Dr Awan on the Impact of CAR T-Cell Therapy on the CLL Treatment Paradigm

January 15th 2025

Farrukh Awan, MD, delves into CAR T-cell therapy and its impact on the chronic lymphocytic leukemia treatment paradigm.

Dr Lamba on Rapid Long-Read Epigenomic Diagnosis and Prognosis in AML

January 15th 2025

Jatinder Lamba, PhD, MSc, discusses the potential clinical application of rapid long-read sequencing for the diagnosis of acute myeloid leukemia.

Dr Montero on Zanidatamab and Evorpacept in HER2-Expressing Metastatic Breast Cancer

January 15th 2025

Alberto Montero, MD, MBA, CPHQ, discusses data with the combination of zanidatamab and evorpacept in HER2-positive and HER2-low metastatic breast cancer.

Dr Graff on Fertility Preservation Strategies in Breast Cancer

January 15th 2025

Stephanie L. Graff, MD, FACP, FASCO, discusses current strategies for fertility preservation in patients with breast cancer.

Dr Graff on the Efficacy and Safety of GnRH Agonists for Premenopausal Women With Breast Cancer

January 15th 2025

Stephanie L. Graff, MD, FACP, FASCO, discusses data supporting the use of GnRH agonists for premenopausal women with breast cancer undergoing chemotherapy.

Dr Ruella on Improving Access to CAR T-Cell Therapy for Minority Populations in Multiple Myeloma

January 15th 2025

Marco Ruella, MD, discusses strategies to improve access to CAR T-cell therapy for the management of multiple myeloma in minority health populations.

Dr van den Brink on a High-Fiber Dietary Intervention in Smoldering Multiple Myeloma

January 14th 2025

Marcel van den Brink, MD, PhD, discusses a high-fiber dietary intervention for early-stage plasma cell disorders designed for multiple myeloma

Dr Levy on Challenges With TROP2-Directed ADCs in NSCLC

January 14th 2025

Benjamin P. Levy, MD, shares insight on current challenges with TROP2-directed antibody-drug conjugates in NSCLC.

Dr Ruella on Access Disparities to CAR T-Cell Therapy in Minority Patients With Myeloma

January 14th 2025

Marco Ruella, MD, discusses disparities in access to commercial anti-BCMA CAR T-cell therapy among minority populations (MHPs) with multiple myeloma.

Dr Park on Patient and Disease Factors that Affect Treatment Decisions for mHSPC

January 13th 2025

Chandler Park, MD, FACP, discusses patient characteristics, disease factors, and drug mechanisms of action that influence treatment decisions in mHSPC.

Dr Ghia on a Pooled Analysis of OS Outcomes With Ibrutinib Plus Venetoclax in CLL

January 13th 2025

Paolo Ghia, MD, PhD, discusses OS outcomes with first-line ibrutinib plus venetoclax in patients with CLL vs an age-matched general European population.

Dr Piotrowska on the Importance of Genomic Profiling to Identify HER2 Mutations in NSCLC

January 13th 2025

Zosia Piotrowska, MD, MHS, discusses the importance of differentiating between HER2 alterations among patients with non–small cell lung cancer.

Dr Strickler on the Rationale for Evaluating Telisotuzumab Adizutecan in Gastric/GEJ Cancer

January 13th 2025

John H. Strickler, MD, details the rationale for evaluating telisotuzumab adizutecan in advanced gastric/GEJ cancer.

Dr Girard on Mechanisms of Action for TKIs vs ADCs in HER2-Mutated NSCLC

January 13th 2025

Nicolas Girard, MD, discusses differences in the mechanisms of action for HER2-directed TKIs vs antibody-drug conjugates in HER2-mutant NSCLC.